Figures & data
Figure 1 Anti-NMDA receptor antibodies in patient’s cerebrospinal fluid and serum. Anti-NMDA receptor antibodies were positive in cerebrospinal fluid (IgG, 1:32) (A) and serum (IgG, 1:320) (B) before immunotherapy. The level of anti-NMDA receptor antibodies significantly decreased in cerebrospinal fluid (IgG, 1:3.2) (C) and serum (IgG, 1:32) (D) after 5 months of immunotherapy.
![Figure 1 Anti-NMDA receptor antibodies in patient’s cerebrospinal fluid and serum. Anti-NMDA receptor antibodies were positive in cerebrospinal fluid (IgG, 1:32) (A) and serum (IgG, 1:320) (B) before immunotherapy. The level of anti-NMDA receptor antibodies significantly decreased in cerebrospinal fluid (IgG, 1:3.2) (C) and serum (IgG, 1:32) (D) after 5 months of immunotherapy.](/cms/asset/8237c4f9-2086-4cab-9dca-be1c67b5410d/dndt_a_195706_f0001_c.jpg)
Table 1 Clinical similarities, differences, and diagnostic features in anti-NMDA receptor encephalitis and NMS